Talon Private Wealth LLC Purchases New Position in Bristol-Myers Squibb (NYSE:BMY)

Talon Private Wealth LLC acquired a new stake in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 5,512 shares of the biopharmaceutical company's stock, valued at approximately $312,000.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Morse Asset Management Inc lifted its stake in Bristol-Myers Squibb by 25.0% in the 3rd quarter. Morse Asset Management Inc now owns 10,000 shares of the biopharmaceutical company's stock valued at $517,000 after buying an additional 2,000 shares in the last quarter. Tudor Financial Inc. acquired a new position in shares of Bristol-Myers Squibb during the third quarter valued at approximately $250,000. Pine Valley Investments Ltd Liability Co lifted its position in shares of Bristol-Myers Squibb by 1.3% in the third quarter. Pine Valley Investments Ltd Liability Co now owns 44,897 shares of the biopharmaceutical company's stock valued at $2,323,000 after acquiring an additional 575 shares in the last quarter. World Investment Advisors LLC boosted its stake in shares of Bristol-Myers Squibb by 18.7% in the third quarter. World Investment Advisors LLC now owns 44,106 shares of the biopharmaceutical company's stock worth $2,282,000 after acquiring an additional 6,954 shares during the last quarter. Finally, Arvest Bank Trust Division purchased a new stake in shares of Bristol-Myers Squibb during the third quarter worth approximately $1,724,000. Institutional investors and hedge funds own 76.41% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on BMY. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $55.00 target price on shares of Bristol-Myers Squibb in a research note on Tuesday, April 22nd. Piper Sandler initiated coverage on shares of Bristol-Myers Squibb in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 price objective for the company. Jefferies Financial Group decreased their target price on shares of Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a research note on Wednesday, April 23rd. The Goldman Sachs Group restated a "neutral" rating and issued a $55.00 price target (down from $67.00) on shares of Bristol-Myers Squibb in a research report on Tuesday, April 8th. Finally, Argus raised Bristol-Myers Squibb to a "hold" rating in a research note on Friday, April 25th. Two investment analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have given a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $58.00.

Insider Transactions at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat purchased 4,250 shares of the firm's stock in a transaction on Friday, April 25th. The stock was bought at an average cost of $47.58 per share, with a total value of $202,215.00. Following the acquisition, the executive vice president now directly owns 83,513 shares of the company's stock, valued at approximately $3,973,548.54. This represents a 5.36 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 0.09% of the company's stock.

Bristol-Myers Squibb Stock Down 3.3 %

Shares of BMY traded down $1.65 during mid-day trading on Tuesday, hitting $48.41. 6,464,913 shares of the company's stock were exchanged, compared to its average volume of 12,943,821. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. The company has a market cap of $98.51 billion, a price-to-earnings ratio of -10.97, a P/E/G ratio of 2.07 and a beta of 0.39. The stock's 50-day moving average is $55.53 and its 200-day moving average is $56.39. Bristol-Myers Squibb has a fifty-two week low of $39.35 and a fifty-two week high of $63.33.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping the consensus estimate of $1.50 by $0.30. The business had revenue of $11.20 billion during the quarter, compared to the consensus estimate of $10.77 billion. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The company's quarterly revenue was down 5.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($4.40) earnings per share. On average, sell-side analysts anticipate that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, May 1st. Stockholders of record on Friday, April 4th were paid a $0.62 dividend. This represents a $2.48 annualized dividend and a dividend yield of 5.12%. The ex-dividend date was Friday, April 4th. Bristol-Myers Squibb's payout ratio is presently 92.88%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.